



## In Vivo Microscopy: Applications in Pulmonary Pathology

Lida Hariri, MD, PhD

Department of Pathology Pulmonary and Critical Care Unit Wellman Center for Photomedicine Massachusetts General Hospital, Boston, MA




lhariri@partners.org



Disclosures

# No relevant financial relationships with commercial interests to disclose


## High Resolution Imaging: Bridging the Radiology/Pathology Divide



### **Examples of Imaging Modalities that provide IVM**

- Optical coherence tomography
- Photoacoustic tomography
- Confocal and multiphoton microscopy
- Spectroscopy
  - Raman spectroscopy
  - Near infrared spectroscopy

# **Optical Coherence Tomography**




transverse

#### **Analogous to Ultrasound**

- Cross-sectional (x-z) imaging of tissue structure
- Similar to low power microscopy(2x-4x objective)
  - < 10 µm axial resolution (z)

- 10-30 µm transverse resolution (x)
- < 3 mm penetration depth
- Non-destructive
- No transducing medium


## **OCT** Applications: Retinal and Intravascular



Drexler W et al. Progress in Retinal and Eye Research. 27(1). 2008



http://buea.net/services-offered/retina/



Tearney et al. JACC Cardiovasc Imaging. 1(6). 2008.

# High Resolution Imaging in Pulmonary Pathology

### Pulmonary Nodules- Is it Cancer? Currently Used Biopsy Guidance Techniques in the Lung

#### Endobronchial Ultrasound



#### Electromagnetic Navigation




### Diagnostic Yield is still low for lesions < 3.0 cm

Thursday, July 2, 15


# Lung Nodule Biopsies



# OCT to Guide Bronchoscopic Biopsy



## Needle-based OCT probe




#### Flexible OCT imaging probe easily placed within standard 21-gauge TBNA needle

### Image and biopsy with same needle



Tan KM et al. Biomed Opt Express. 3(8):1947-54. 2012


## Bronchoscopic Biopsy



Thursday, July 2, 15

12

## Transbronchial Needle Aspiration



# OCT Criteria for Nodule and Lung Parenchyma


- Develop OCT criteria for peripheral nodule and lung parenchyma in ex vivo lung resection specimens
- Validate OCT criteria in a blinded assessment with 6 independent readers
  - Two pathologists, pulmonologists, and OCT experts
  - 15 minute training on criteria
  - Validation Set: 109 ex vivo samples
  - Include a variety of pathology for nodules and parenchyma

### Assess: Nodule or Parenchyma

## Needle-based OCT

## Lung Parenchyma

5 mm



Hariri LP et al. Chest. 144(4):1261-8.2013


## How did everyone do? Sensitivity and Specificity

	<b>OFDI Experts</b>	Pathologists	Pulmonologists
Sensitivity	99.1 ± 1.3	93.5 ± 6.6	93.5 ± 6.6
Specificity	99.1 ± 1.3	98.2 ± 2.6	97.3 ± 3.9
Accuracy	99.1 ± 1.3	95.9 ± 1.9	95.4 ± 1.3
	<b>All OFDI Readers</b>		
Sensitivity	95.4 ± 5.1		
Specificity	98.2 ± 2.3		
Accuracy	96.8 ± 2.1		

High sensitivity and specificity (> 95%) for all readers OCT can aid in determining if biopsy needle is in the nodule or adjacent parenchyma

Hariri LP et al. Chest. 144(4):1261-8.2013

## Tumor Versus Non-diagnostic Contaminants




#### Structural OCT can differentiate tumor from:

Airway
Parenchyma
Necrosis

**Cannot differentiate solid tumor from fibrosis** 


Hariri LP et al. AJRCCM. 187(2):125-9.2013

### Polarization Sensitive OCT visualizes fibrosis



Hariri LP et al. AJRCCM. 187(2):125-9.2013

# OCT Guidance in Bronchial Biopsy: The Complete Picture




### Can OCT aid in diagnosing lung CA? Potential to replace biopsy?

In this study:

- Develop/validate OCT criteria for common lung carcinomas
- Three blinded readers are trained on OCT criteria and assess 78 tumor samples from ex vivo resection specimens
  - 36 AdenoCA, 23 SCC, 19 poorly differentiated carcinoma


## Squamous Cell Carcinoma




A. Signal intense (bright) nests, round/irregularly shaped (Green Arrows)
B. May have variably sized, irregularly-shaped signal poor areas of necrosis Either admixed with nests (Red Box) or in center of nests (Red Arrow)

Hariri LP et al. Annals ATS. 2015

# Squamous Cell Carcinoma




## Adenocarcinoma




A. Round or angulated signal poor structures (Blue Arrows) Typically small, but may vary in size
B. Lack of signal intense (bright) nests

Hariri LP et al. Annals ATS. 2015

## Adenocarcinoma



## Poorly Differentiated Carcinoma



A. Lack of round/angulated signal poor structuresB. Lack of signal intense (bright) nests

### **Results:** OCT in lung CA diagnostics

	AdenoCA	SCC	PDC
Sensitivity	80.3%	83.3%	85.7%
	(66-92%)	(70-100%)	(81-95%)
Specificity	88.6%	87%	97.6%
	(81-98%)	(75-97%)	(93-100%)
Accuracy	82.6% (74-95%)		

### Conclusions: OCT in lung CA diagnostics

Overall average accuracy was 82% with > 80% sensitivity and specificity Wide range suggests potential for improvement with further training OCT Expert achieved >95% accuracy

#### **Take Home Message**

#### OCT has potential to complement, but not replace, tissue biopsy

Guide intramass tissue sampling towards areas of diagnostic material Specificity for PDC high so readers identified when features were present Identify tumor regions with better differentiation during biopsy

Need to validate findings in clinical in vivo study


### "Will IVM replace traditional pathology?"

# <u>No</u>

- Sensitivity/specificity not high enough
- Resolution not high enough
- Differential diagnosis in many scenarios is vast
- You are there, take a biopsy!
- Molecular testing requires physical tissue


## Future Directions in Lung Cancer

- In vivo study to assess diagnostic yields of transbronchial biopsy with and without OCT guidance
- Assess diagnostic capability of OCT+biopsy vs biopsy alone
- Can optical imaging provide "virtual tissue" with additional diagnostic information when added to traditional biopsy?




High Resolution Imaging in Pulmonary Pathology: Snapshots of New Upcoming Things


### Higher Precision Tumor Measurements Over Therapy




#### **OCT** visualizes tumor angiogenesis over time





**PS-OCT** identifies regions of fibrotic stroma in tumor





Vakoc B et al. Nature Med 2009.






**Optical** scattering properties delineate necrotic (redyellow) and viable (bluegreen) tumor regions

Thursday, July 2, 15

### Moving towards even higher resolution in OCT So far just ex vivo....



### Atherosclerotic Plaque

### Normal Lung

Jain M. J Path Inform. 4(26). 2013

Liu L, et al. Nat Med. 17(8). 2011

Thursday, July 2, 15

### In vivo microscopy needs a defined expert: <u>Pathologists</u>

- In radiology, many clinicians can assess CT scans but that does not make them radiologists
- Similarly, many clinicians may use and interpret IVM
- IVM is in essence a form of microscopy, and as such pathologists are the obvious choice as IVM experts

### IVM needs a defined expert: Pathologists

Pathologist inherently have the skills needed to become IVM experts, but we need to gain experience to accomplish this

Collaborate in IVM studies
Identify clinical scenarios where IVM can make impacts, especially in pathology

Participate in ex vivo and in vivo validation studies

## Acknowledgements

#### **Suter Optical Imaging Laboratory**

Melissa Suter, PhD David Adams, PhD Alyssa Miller Yan Wang, PhD Helene Stroh Alex Chee, MD Eddie Tan, PhD

#### **MGH Department of Pathology**

Mari Mino-Kenudson, MD Eugene Mark, MD Stephen Conley, BS

#### **Wellman Center for Photomedicine**

Brett Bouma, PhD Guillermo Tearney, MD, PhD Martin Villiger, PhD Milen Shishkov, PhD Photopathology



#### MGH Pulmonary and Critical Care

Benjamin Medoff, MD Colleen Channick, MD Colleen Keyes, MD

#### **MGH Thoracic Surgery**

Michael Lanuti, MD

#### **Funding Sources**

National Institute of Health

- R01CA167827
- R00CA134920
- P41EB015903
- •T32CA009216